Applying DanGer Shock Eligibility Criteria to a Real-World Cohort of Cardiogenic Shock Patients.

ABSTRACT:

Background

The DanGer Shock trial investigated the effects of adding a microaxial flow pump to guideline-recommended therapy in patients with ST-elevation myocardial infarction (STEMI)-related cardiogenic shock (CS), finding a lower all-cause mortality at 180 days in the intervention group.

Methods

DanGer Shock eligibility criteria were applied to the prospective single-center PREPARE CardShock registry, which consecutively enrolled 721 patients between April 2019 and August 2024 with advanced CS-classified as stages C to E according to the SCAI shock classification-who were on vasoactive medication and underwent cardiac catheterization.

Results

Among 721 patients in the registry, 384 (53.3%) had STEMI-related CS. Of those, 117 (30.5%) met DanGer Shock trial eligibili

SUBMITTER: Planka RM 

PROVIDER: S-EPMC12679520 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature